OCUMENSION-B(01477): The first patient has been enrolled in the Phase III clinical trial of OT-211.

Alcon Inc. (together with its affiliated companies referred to as "Alcon Group") announced that the phase III clinical trial of OT-211 (AR-15512) conducted in China has completed the enrollment of the first patient. OT-211 (AR-15512) is a 0.003% eye drop formula, also the first FDA-approved TRPM8 agonist for the treatment of Dry Eye Disease (DED). The successful enrollment of the first patient marks an important milestone in the clinical development of OT-211 in China, demonstrating the group's commitment to advancing innovative therapies for DED patients. Alcon Group is a global leader in eye care, with business covering surgical and vision care sectors. They developed the 0.003% concentration eye drop formula of AR-15512 and completed a phase IIb and three phase III clinical trials. OT-211 (AR-15512) was approved by the FDA on May 28, 2025 for the treatment of signs and symptoms of DED. After a strategic partnership with Alcon Group in October 2024, the group has obtained exclusive license from Alcon Group to develop, manufacture, contract manufacture, import, export, and sell OT-211 (AR-15512) in mainland China.